Prostate Neoplasms

Oncology·MeSH: Prostatic Neoplasms

Prevalence

3358.2 / 100K

Incidence

1547.2 / 100K/yr

23 drugs in development·7 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
Cetrelimab	KYNTRA BIO INC. (KYNB)
Darolutamide	ARS Pharmaceuticals, Inc. (SPRY)
Enzalutamide	Myovant Sciences Ltd. (MYOV)
pasritamig	GH Research PLC (GHRS)

Phase 2(3)

Phase 1(15)

Drug	Company
Apalutamide	Merus N.V. (MRUS)
Apalutamide	Janux Therapeutics, Inc. (JANX)
Cabazitaxel	Merus N.V. (MRUS)
Cabazitaxel	Myovant Sciences Ltd. (MYOV)
Cabazitaxel	Royalty Pharma plc (RPRX)
Cabazitaxel	ARS Pharmaceuticals, Inc. (SPRY)
Cetrelimab	ARS Pharmaceuticals, Inc. (SPRY)
Cetrelimab	Myovant Sciences Ltd. (MYOV)
Enzalutamide	Janux Therapeutics, Inc. (JANX)
jnj-101556143	GH Research PLC (GHRS)
JNJ-78278343	Royalty Pharma plc (RPRX)
JNJ-78278343	ARS Pharmaceuticals, Inc. (SPRY)
JNJ-78278343	KYNTRA BIO INC. (KYNB)
JNJ-78278343	Myovant Sciences Ltd. (MYOV)
JNJ-78278343	Merus N.V. (MRUS)

Phase 4(1)

Drug	Company
Enzalutamide	Royalty Pharma plc (RPRX)

BioSniper tracks 23 drugs in development for Prostate Neoplasms across 7 companies.

There are 3 clinical trials targeting Prostate Neoplasms tracked by BioSniper.

The estimated prevalence of Prostate Neoplasms is approximately 3358.2 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.